Form 8-K - Current report:
SEC Accession No. 0001193125-23-146584
Filing Date
2023-05-17
Accepted
2023-05-17 08:15:31
Documents
14
Period of Report
2023-05-17
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d490821d8k.htm   iXBRL 8-K 25333
2 EX-99.1 d490821dex991.htm EX-99.1 27667
6 GRAPHIC g490821g0517065341767.jpg GRAPHIC 4112
  Complete submission text file 0001193125-23-146584.txt   188278

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tcrx-20230517.xsd EX-101.SCH 2845
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tcrx-20230517_lab.xml EX-101.LAB 17979
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tcrx-20230517_pre.xml EX-101.PRE 11255
8 EXTRACTED XBRL INSTANCE DOCUMENT d490821d8k_htm.xml XML 3351
Mailing Address 880 WINTER STREET WALTHAM MA 02451
Business Address 880 WINTER STREET WALTHAM MA 02451 857-399-9500
TScan Therapeutics, Inc. (Filer) CIK: 0001783328 (see all company filings)

EIN.: 825282075 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40603 | Film No.: 23929686
SIC: 2836 Biological Products, (No Diagnostic Substances)